Nuvation Bio Teams with Westwood & Wilshire to Place Chief Medical Officer

July 18, 2022 07:00 AM

NEW YORK- Dr. Liu joins Nuvation Bio from 3D Medicines, where he served as Chief Medical Officer overseeing all clinical research activities for a genetics- based precision cancer platform. Prior, Dr. Liu spent 15 years with Bristol Myers Squibb and Celgene where he served as the Global Lead for the combination revlimid/rituximab program for indolent lymphoma. At BMS, he notably led clinical development and translational research for nivolumab and ipilimumab in China. In addition to his MD from Being Medical University, Dr. Liu received his Ph.D in Biology from MIT.

The search was led successfully by Ayn Teigman.

Client Background

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to- treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D.,

About Westwood & Wilshire

Westwood & Wilshire is a retained executive-search firm delivering premier talent in life sciences, healthcare and advanced technology to the world’s most innovative companies. Our specialty is bringing top-flight senior leadership to growing venture-backed companies looking for the best people to fill their C-Suite hires. Clients around the globe work with Westwood & Wilshire to build world-changing companies. Contact information can be found at https://westwoodwilshire.com/contact-us.